BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AC Immune SA Raises CHF 21 Million In Private Financing Round


10/19/2005 5:10:20 PM

ECUBLENS and LAUSANNE, Switzerland, May 11 /PRNewswire/ -- AC Immune, a Swiss biotech company developing innovative therapies against Alzheimer's disease, today announced that it has successfully completed its round B financing raising CHF 21 million from private and strategic investors. The financing goal of CHF 21 millions was achieved with 2/3 of the invested capital contributed by new investors.

AC immune is focused on new therapies for the treatment of Alzheimer's disease using vaccination or passive immunization with antibodies. Both the active and passive immunotherapy is directed against the beta amyloid protein which misfolds and forms plaques in Alzheimer's disease. The patent-protected antigen technology of AC Immune provides highly efficient immunization and solubilization of the plaques by inducing transition from the insoluble to the soluble from of the beta amyloid protein. AC Immune's pipeline comprises 3 compounds entering in clinical development in 2006/2007. The latest financing provides the funds to complete Phase I of at least one molecule in development.

"After obtaining encouraging results in animal studies showing the unique features of AC Immune's immunotherapeutic approach, we are very excited to move into the next phase of testing our lead molecules for clinical submission", said Andrea Pfeifer, CEO of AC Immune.

"There is an outstanding market opportunity in Alzheimer's and conformational diseases, said Martin Velasco, Chairman of the Board of AC Immune. "Our investors and management share a common vision to leverage AC Immune's innovative approach in order to efficiently bring therapeutic solutions to the market."

The successful financing was built on the continuous trust of both existing and new investors in the company's technological edge, its intellectual property and the management capability to lead the company from preclinical into clinical development.

Contact Dr. Andrea Pfeifer CEO AC Immune Phone: +(41)21-693-91-22 E-mail: andrea.pfeifer@acimmune.com

A photo portrait of Dr. Andrea Pfeifer is available from Violaine Dallenbach, Rochat & Partners, tel. +41(0)22-718-37-42 / e-mail: vdallenbach@rochat-pr.ch

About AC Immune

AC Immune is a privately held company focusing on the development of therapies against Alzheimer's disease, a so-called conformational disease. AC Immune is using its proprietary immunology platform to develop active and passive immunotherapies, i.e. vaccine and monoclonal antibodies, against Alzheimer's disease, directly reducing the toxic ss-amyloid plaques in the brain. AC Immune's proprietary immunology platform technology brings the ability to break the immune tolerance to "self" proteins by generating conformation-sensitive antibodies that lead to the creation of active and passive immune therapies. The company's products are in the preclinical stage and the first product will enter clinical phase I in 2006.

The company was founded in February 2003 in Basel, Switzerland. Our team of experienced managers and scientists is located in Ecublens, Switzerland, and in the laboratories at the Institut de Science et d'Ingenierie Supramoleculaires (ISIS) in Strasbourg, France.

AC Immune's intellectual property is based on research performed by Claude Nicolau, Ph.D., founder and an international leader in cellular biophysics, and Jean-Marie Lehn, Ph.D., Nobel Prize winner in Chemistry, College de France, Paris and Universite Louis Pasteur, Strasbourg, and specialist in molecular recognition and supramolecular chemistry.

AC Immune works closely with large pharma companies and is seeking strategic alliances for the development of its vaccine- and antibody-based Alzheimer's drugs.

www.acimmune.com

AC Immune

CONTACT: Contact: Dr. Andrea Pfeifer, CEO, AC Immune, Phone:+(41)21-693-91-22, E-mail: andrea.pfeifer@acimmune.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES